Paul Tudor Jones's CRL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 92,717 shares of Charles River Laboratories International, Inc. (CRL) worth $14.51 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2016, adding 244,223 shares. Largest reduction occurred in Q3 2016, reducing 153,937 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +9,601 | Add 0.00% | 9,600 | $41.04 |
| Q3 2013 | -900 | Reduce 9.38% | 8,700 | $46.21 |
| Q4 2013 | +600 | Add 6.90% | 9,300 | $53.01 |
| Q1 2014 | +7,461 | Add 80.23% | 16,761 | $60.32 |
| Q2 2014 | +1,333 | Add 7.95% | 18,094 | $53.50 |
| Q3 2014 | -6,294 | Reduce 34.79% | 11,800 | $59.75 |
| Q4 2014 | -3,100 | Reduce 26.27% | 8,700 | $63.68 |
| Q1 2015 | +1,422 | Add 16.34% | 10,122 | $79.33 |
| Q2 2015 | -1,268 | Reduce 12.53% | 8,854 | $70.36 |
| Q3 2015 | +7,215 | Add 81.49% | 16,069 | $63.54 |
| Q4 2015 | +4,267 | Add 26.55% | 20,336 | $80.40 |
| Q1 2016 | +244,223 | Add 1200.94% | 264,559 | $75.94 |
| Q2 2016 | -101,722 | Reduce 38.45% | 162,837 | $82.44 |
| Q3 2016 | -153,937 | Reduce 94.53% | 8,900 | $83.37 |
| Q4 2016 | -380 | Reduce 4.27% | 8,520 | $76.17 |
| Q1 2017 | +2,704 | Add 31.74% | 11,224 | $89.99 |
| Q2 2017 | -4,914 | Reduce 43.78% | 6,310 | $101.11 |
| Q3 2017 | -6,310 | Sold Out | 6,310 | $0.00 |
| Q3 2019 | +5,190 | New Buy | 5,190 | $132.37 |
| Q4 2019 | -2,663 | Reduce 51.31% | 2,527 | $152.75 |
| Q1 2020 | +1,045 | Add 41.35% | 3,572 | $126.26 |
| Q2 2020 | -3,572 | Sold Out | 3,572 | $0.00 |
| Q4 2020 | +8,852 | New Buy | 8,852 | $249.89 |
| Q1 2021 | +4,934 | Add 55.74% | 13,786 | $289.86 |
| Q2 2021 | -10,418 | Reduce 75.57% | 3,368 | $369.95 |
| Q3 2021 | -3,368 | Sold Out | 3,368 | $0.00 |
| Q4 2021 | +11,391 | New Buy | 11,391 | $376.79 |
| Q1 2022 | +1,075 | Add 9.44% | 12,466 | $283.97 |
| Q2 2022 | +3,727 | Add 29.90% | 16,193 | $213.98 |
| Q3 2022 | -16,193 | Sold Out | 16,193 | $0.00 |
| Q3 2023 | +57,173 | New Buy | 57,173 | $195.98 |
| Q4 2023 | +8,744 | Add 15.29% | 65,917 | $236.40 |
| Q1 2024 | -45,222 | Reduce 68.60% | 20,695 | $270.95 |
| Q2 2024 | -1,697 | Reduce 8.20% | 18,998 | $206.58 |
| Q3 2024 | -18,998 | Sold Out | 18,998 | $0.00 |
| Q4 2024 | +56,286 | New Buy | 56,286 | $184.60 |
| Q1 2025 | +12,839 | Add 22.81% | 69,125 | $150.52 |
| Q2 2025 | +100,669 | Add 145.63% | 169,794 | $151.73 |
| Q3 2025 | -77,077 | Reduce 45.39% | 92,717 | $156.46 |
Paul Tudor Jones's Charles River Laboratories International Investment FAQs
Paul Tudor Jones first purchased Charles River Laboratories International, Inc. (CRL) in Q2 2013, acquiring 9,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Charles River Laboratories International, Inc. (CRL) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q1 2016, adding 264,559 shares worth $20.09 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 92,717 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $14.51 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Charles River Laboratories International, Inc. (CRL) was 264,559 shares, as reported at the end of Q1 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.